Term ends Oct 1, 2030 · High confidence
20-year base term ends Oct 1, 2030
Oct 1, 2010
Oct 1, 2030
Jul 24, 2018
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 1, 2010, when application PCT/IB2010/002613, the earliest non-provisional in its chain, was filed (this one was filed Sep 10, 2012) | Oct 1, 2030 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,618,081, US 8,865,139, US 8,871,184, US 8,945,516, US 8,992,896) | resolves to Oct 1, 2030, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 1, 2030 | High confidence |
Partial family
| Application PCT/IB2010/002612 | PCT application no patent term | no patent term |
| Application PCT/IB2010/002613 | PCT application no patent term | no patent term |
| Application PCT/IB2010/002617 | PCT application no patent term | no patent term |
| Application PCT/IB2020/002612 | PCT application no patent term | no patent term |
| US 8,618,081 | In force Oct 2030 | Oct 2030 |
| Application PCT/IB2011/001374 | PCT application no patent term | no patent term |
| US 8,945,516 | Lapsed on the fee record Feb 2023 | Feb 2023 |
| US 10,029,013 | this patent Oct 2030 | Oct 2030 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 11, 2012 Reel 28938, frame 176 | Tamarkin, Dov; Gazal, Elana; Papiashvili, Irakliy; Hazot, Yohan; Schuz, David; Keynan, Rita | Foamix Ltd. | Assignment of Assignor's Interest |
| Jul 30, 2014 Reel 33445, frame 249 | Foamix Ltd. | Foamix Pharmaceuticals Ltd. | Change of Name |
| Jul 30, 2019 Reel 49912, frame 45 | Foamix Pharmaceuticals Ltd. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Nov 4, 2020 Reel 54306, frame 387 | Foamix Pharmaceuticals Ltd. | Vyne Pharmaceuticals Ltd. | Change of Name |
| Feb 4, 2021 Reel 55215, frame 298 | Vyne Pharmaceuticals Ltd. | Vyne Therapeutics Inc. | Assignment of Assignor's Interest |
| Feb 17, 2021 Reel 55326, frame 9 | Vyne Therapeutics Inc. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Sep 20, 2021 Reel 57544, frame 138 | Perceptive Credit Holdings II, LP | Vyne Pharmaceuticals Ltd. (F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Sep 20, 2021 Reel 57544, frame 708 | Perceptive Credit Holdings II, LP | Vyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
| Dec 22, 2021 Reel 58463, frame 167 | Vyne Therapeutics Inc. | Vyne Pharmaceuticals Inc. | Assignment of Assignor's Interest |
| Feb 1, 2022 Reel 58925, frame 568 | Vyne Therapeutics Inc.; Vyne Pharmaceuticals Inc. | Journey Medical Corporation | Assignment of Assignor's Interest |
| Dec 28, 2023 Reel 66157, frame 79 | Journey Medical Corporation; JG Pharma, Inc. | SWK Funding LLC | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 8,618,081, US 8,865,139, US 8,871,184, US 8,945,516, US 8,992,896, ends no earlier than this term, so it caps nothing.